Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (660)	4/20/1998 12:40:00 AM
From: Richard Haugland	Read Replies (1) \| Respond to of 1728

Steve, I have heard of the HYSQ versus AFFX patent situations but have never really studied the claims of either party. Thus, I don't feel qualified to comment on the matter. I did look at the HYSQ patent once but don't remember what I concluded. There are a number of players in this field but I recognize the name of AFFX much more than HYSQ. AFFX is building production facilities near Sacramento, which I looks as a big move toward profitability. I don't know if the $50,000,000 that AFFX got from Glaxo this last week in preferred stock investment will dilute the regular shares but I suspect it will. Of course issuing more shares when one is losing money actually LOWERS the figure for loss when calculated as a "loss per share" and make it appear that the company actually has beaten the analysts' estimates. If that is true the effect will not be seen until reporting on the current quarter. I had no problem getting around Vysis' web site. This is the link to their numerous press releases, several of which are from before they went public. vysis.com You are right on BCRX. Moved from 6 5/8 to 9 on Friday. I found this on the Yahoo board: BCRX: 200,000 share order by institutional investor being filled . Complete order not filled Friday . Investor started with instructions to pay up to $9.00 a share. With thin float stock could go higher Monday. There was a 60,000 or so share trade at <$8 so this could be correct. Could be interesting Monday.